ODI Pharma
Manufacturing · United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.odipharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About ODI Pharma
ODI Pharma AB is a pharmaceutical company specializing in the production and distribution of medicinal cannabis products across Europe, particularly targeting medicinal markets in Eastern Europe. Established in 2018, the company aims to improve patients' lives by providing high-quality, medical-grade pharmaceuticals under strict governmental supervision. With a robust distribution network, ODI Pharma has established contracts with over 14,000 pharmacies, numerous specialty clinics, and hospitals. The company is committed to supporting the medical industry and advancing research in the field of medicinal cannabis.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ODI Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when ODI Pharma launches new products
Check out if ODI Pharma is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if ODI Pharma has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once ODI Pharma has new funding data
ODI Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at ODI Pharma
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on ODI Pharma recently announced quarterly report
Click to see if ODI Pharma had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to ODI Pharma
Compare insights from companies similar to ODI Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
ODI Pharma
<$5M
1-10
Private
-
-
N/A
Company Profile Activity
Activity Insights
ODI Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ODI Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ODI Pharma.
ODI Pharma Tech Stack
A closer look at the technologies used by ODI Pharma
ODI Pharma News & Media
ODI Pharma achieved market share targets in 2024 and increases its targets for 2025. Positioned for growth as Poland's medical cannabis market expands.
ODI Pharma AB ("ODI" or the "Company") provides an update on Poland’s expanding medical cannabis market, which remains an important focus of the Company’s strategy. Recent regulatory changes in Poland highlight ODI’s established position in one of Europe’s most promising markets for medical cannabis. With ODI Pharma’s sales during the current calendar year, ODI Pharma reached it’s previously stipulated goal of achieving a substantial market share of more than 10%, resulting in a positive operatiNotice of Extraordinary General Meeting in ODI Pharma AB (publ)
The shareholders of ODI Pharma AB (publ), 559223-1392, are hereby invited to an Extraordinary General Meeting to be held on Tuesday 19 November 2024 at 14.30 at the company's premises at Östermalmstorg 1, 114 42 in Stockholm. Eligibility and registration Shareholders who wish to participate in the General Meeting shall · be entered in the share register maintained by Euroclear Sweden AB on 11 November 2024, and · notify the company no later than onProposal for change in the Board of Directors of ODI Pharma AB
Malcolm Allan is proposed to be elected as a new member of the Board of Directors of ODI Pharma AB at the Extraordinary General Meeting on November 19, 2024. Malcolm Allan has extensive experience in senior positions within global companies and political campaigns. For the past three years, he has been serving as Vice President at Tilray Brands Inc. Prior to that, he was the Global COO for Havas Media and Managing Director for PrudentialODI Pharma AB decides on a preferential issue of shares and to bring forward publication of the Q1-report
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM SWEDISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE. The Board of Directors of ODI Pharma AB ("ODI"
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ODI Pharma
Sign Up For FreeTo access detailed company insights
ODI Pharma AB is a pharmaceutical company specializing in the production and distribution of medicinal cannabis products across Europe, particularly targeting medicinal markets in Eastern Europe. Established in 2018, the company aims to improve patients' lives by providing high-quality, medical-grade pharmaceuticals under strict governmental superv... Read More
